查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1522132

子宮內膜癌市場 - 全球產業規模、佔有率、趨勢、機會和預測，按癌症類型、治療、診斷方法、最終用途、地區和競爭細分，2019-2029F

Endometrial Cancer Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Cancer Type, By Therapy, By Diagnosis Method, By End Use, By Region and Competition, 2019-2029F
出版日期: | 出版商: TechSci Research | 英文 188 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2023 年全球子宮內膜癌市場價值為283.2 億美元，預計在預測期內將出現令人印象深刻的成長，到2029 年複合年成長率為5.23%。是一種起源於子宮的惡性腫瘤。它是最常見的婦科癌症之一，主要影響停經後婦女，但也可能發生在年輕人身上。當子宮內膜細胞發生異常變化並開始不受控制地生長和繁殖時，就會發生子宮內膜癌。子宮內膜癌最常見的症狀是陰道異常出血，尤其是停經後婦女或仍在月經期間的不規則出血。其他症狀可能包括骨盆疼痛、性交疼痛或排尿習慣改變。子宮內膜癌主要有兩種：1 型，通常與過量雌激素暴露有關，通常預後較好；2 型，較不常見，且更具侵襲性。

市場概況
預測期 2025-2029
2023 年市場規模 283.2億美元
2029 年市場規模 380.8億美元
2024-2029 年複合年成長率 5.23%
成長最快的細分市場 免疫療法
最大的市場 北美洲

全球子宮內膜癌市場是指專注於解決和管理子宮內膜癌的產品、服務、治療和技術的整體格局，子宮內膜癌是一種起源於子宮內膜（稱為子宮內膜）的癌症。該市場涵蓋廣泛的干涉措施，包括藥物、外科手術、診斷工具、支持性護理以及旨在預防、早期檢測、治療和改善子宮內膜癌患者預後的研究計劃。該市場包括各種利益相關者，例如開發化療、荷爾蒙治療和對抗癌細胞的標靶療法等新型療法的製藥公司。子宮切除術和放射治療等外科手術也是不可或缺的一部分。影像技術和生物標記測試等診斷工具有助於準確的診斷和預後評估。支持性護理服務和病患教育有助於整體病患管理。全球子宮內膜癌市場受到子宮內膜癌盛行率、醫療技術進步、認知提高、研發投資、監管批准和不斷發展的治療指南等因素的影響。市場的目標是提供有效的干涉措施，改善患者的治療效果，提高生活品質，並減少子宮內膜癌對個人的影響。

主要市場促進因素

癌症盛行率上升

醫療保健支出不斷成長

政府支持舉措

主要市場挑戰

晚期診斷

治療的副作用

主要市場趨勢

個人化醫療的進步

更加重視早期檢測

細分市場洞察

治療見解

癌症類型見解

區域洞察

目錄

第 1 章：產品概述

第 2 章：研究方法

第 3 章：執行摘要

第 4 章：客戶之聲

第 5 章：全球子宮內膜癌市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依癌症類型（子宮內膜癌、子宮肉瘤）
    • 依治療（免疫治療、放射治療、化療、其他類型的治療）
    • 依診斷方法（切片、骨盆超音波、子宮腔鏡檢查、CT 掃描、其他診斷方法）
    • 依最終用途（醫院、影像中心、其他）
    • 按公司分類 (2023)
    • 按地區
  • 市場地圖

第 6 章：北美子宮內膜癌市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按癌症類型
    • 透過治療
    • 按診斷方法
    • 按最終用途
    • 按國家/地區
  • 北美：國家分析
    • 美國
    • 墨西哥
    • 加拿大

第 7 章：歐洲子宮內膜癌市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按癌症類型
    • 透過治療
    • 按診斷方法
    • 按最終用途
    • 按國家/地區
  • 歐洲：國家分析
    • 法國
    • 德國
    • 英國
    • 義大利
    • 西班牙

第 8 章：亞太子宮內膜癌市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按癌症類型
    • 透過治療
    • 按診斷方法
    • 按最終用途
    • 按國家/地區
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲

第 9 章：南美洲子宮內膜癌市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按癌症類型
    • 透過治療
    • 按診斷方法
    • 按最終用途
    • 按國家/地區
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第 10 章：中東和非洲子宮內膜癌市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按癌症類型
    • 透過治療
    • 按診斷方法
    • 按最終用途
    • 按國家/地區
  • MEA：國家分析
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第 11 章：市場動態

  • 促進要素
  • 挑戰

第 12 章：市場趨勢與發展

  • 併購（如有）
  • 產品發布（如有）
  • 最近的發展

第 13 章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 客戶的力量
  • 替代產品的威脅

第14章：競爭格局

  • Elekta
  • Karyopharm Therapeutics Inc.
  • Eisai Co., Ltd
  • GSK plc
  • Siemens Healthineers AG
  • Johnson & Johnson
  • Boston Scientific Corporation
  • Pfizer Inc.
  • Bayer AG
  • Bristol-Myers Squibb Company

第 15 章：策略建議

第16章調查會社について,免責事項

簡介目錄
Product Code: 23988

Global Endometrial Cancer Market was valued at USD 28.32 billion in 2023 and is anticipated to project impressive growth in the forecast period with a CAGR of 5.23% through 2029. Endometrial cancer, also known as uterine cancer, is a type of malignancy that originates in the endometrium, the inner lining of the uterus. It is one of the most common forms of gynecological cancer and primarily affects postmenopausal women, although it can also occur in younger individuals. Endometrial cancer develops when the cells lining the uterus undergo abnormal changes and begin to grow and multiply uncontrollably. The most common symptom of endometrial cancer is abnormal vaginal bleeding, particularly in postmenopausal women or irregular bleeding in those still menstruating. Other symptoms might include pelvic pain, pain during intercourse, or changes in urination habits. There are two main types of endometrial cancer: Type 1, which is often linked to excess estrogen exposure and typically has a better prognosis, and Type 2, which is less common and tends to be more aggressive.

Market Overview
Forecast Period2025-2029
Market Size 2023USD 28.32 Billion
Market Size 2029USD 38.08 Billion
CAGR 2024-20295.23%
Fastest Growing SegmentImmunotherapy
Largest MarketNorth America

The Global Endometrial Cancer Market refers to the collective landscape of products, services, treatments, and technologies focused on addressing and managing endometrial cancer, a type of cancer that originates in the lining of the uterus, known as the endometrium. This market encompasses a wide range of interventions, including pharmaceuticals, surgical procedures, diagnostic tools, supportive care, and research initiatives aimed at prevention, early detection, treatment, and improved outcomes for individuals diagnosed with endometrial cancer. The market includes various stakeholders, such as pharmaceutical companies developing novel therapies like chemotherapy, hormonal treatments, and targeted therapies to combat cancer cells. Surgical procedures like hysterectomy and radiation therapy are also integral components. Diagnostic tools such as imaging technologies and biomarker tests aid in accurate diagnosis and prognosis assessment. Supportive care services and patient education contribute to holistic patient management. The Global Endometrial Cancer Market is influenced by factors like the prevalence of endometrial cancer, advancements in medical technology, increasing awareness, research and development investments, regulatory approvals, and evolving treatment guidelines. The goal of this market is to provide effective interventions that improve patient outcomes, enhance quality of life, and reduce the impact of endometrial cancer on individuals.

Key Market Drivers

Rising Prevalence of cancer

The rising prevalence of endometrial cancer is a significant trend driving the Global Endometrial Cancer Market. Several factors contribute to the increasing occurrence of this cancer type, prompting greater attention to its management and treatment within the healthcare industry. Obesity, a leading risk factor for endometrial cancer, has seen a global surge. Excess body weight can lead to hormonal imbalances, specifically elevated levels of estrogen, which is a key driver of endometrial cancer development. As populations age, the incidence of endometrial cancer rises, as the risk tends to increase with advancing age. Changing lifestyles, including dietary habits and reduced physical activity, are linked to obesity and hormonal imbalances, further exacerbating the risk of endometrial cancer. The prevalence of conditions like polycystic ovary syndrome (PCOS), diabetes, and hypertension, which contribute to hormonal dysregulation, is also on the rise. As awareness about endometrial cancer risk factors spreads, more individuals are seeking medical attention and undergoing screenings, leading to earlier diagnoses. Early detection enhances the chances of successful treatment and improved outcomes. The rising prevalence of endometrial cancer underscores the urgent need for effective treatment options, early detection strategies, and comprehensive patient care. The Global Endometrial Cancer Market is thus positioned to address this growing healthcare challenge by developing innovative therapies, advanced diagnostic tools, and supportive care services that cater to the specific needs of individuals affected by endometrial cancer.

Growing Healthcare Expenditure

The increasing healthcare expenditure is a significant factor influencing the Global Endometrial Cancer Market, as it directly impacts the availability and accessibility of advanced treatments, diagnostics, and patient care services. Governments, private entities, and insurance providers worldwide are allocating more resources to healthcare, reflecting the growing recognition of the importance of addressing complex diseases like endometrial cancer. Higher healthcare budgets contribute to improved infrastructure, state-of-the-art medical facilities, and cutting-edge technologies. For endometrial cancer, this translates to enhanced diagnostic capabilities, such as advanced imaging tools and genetic testing, allowing for more accurate and early detection. Increased healthcare spending supports research and development endeavors, leading to the creation of innovative treatment modalities like targeted therapies, immunotherapies, and personalized medicine approaches. These advancements drive the Global Endometrial Cancer Market by expanding the repertoire of effective treatments available to patients. Growing healthcare expenditure also aids in the establishment of comprehensive care programs, including multidisciplinary teams of specialists, supportive care services, and survivorship programs. These initiatives ensure that patients receive holistic, patient-centered care that addresses not only medical needs but also psychological and emotional well-being. the rising healthcare expenditure fuels progress in the Global Endometrial Cancer Market by fostering advancements in technology, research, treatment options, and patient care infrastructure. It contributes to the overarching goal of improving patient outcomes and enhancing the quality of life for individuals affected by endometrial cancer.

Supportive Government Initiatives

Supportive government initiatives play a pivotal role in shaping the Global Endometrial Cancer Market by creating an environment that fosters research, treatment accessibility, and patient care. Governments worldwide recognize the importance of addressing cancer comprehensively, and their efforts contribute significantly to advancing the field of endometrial cancer management. Government-led initiatives often include funding allocations for cancer research, enabling scientists to explore new treatment avenues, better understand the disease's underlying mechanisms, and develop innovative therapies. This research contributes to the expansion of the Global Endometrial Cancer Market by introducing novel approaches that improve patient outcomes. Supportive policies and regulations ensure that new treatments and technologies undergo rigorous evaluation for safety and efficacy, safeguarding patients and promoting confidence in the healthcare system. This regulatory framework facilitates the introduction of cutting-edge treatments into the market. Government efforts also extend to healthcare infrastructure development, enhancing the accessibility of advanced diagnostic tools and treatment facilities. This accessibility is especially crucial for early detection, timely intervention, and optimal patient care. Public awareness campaigns initiated by governments promote early detection, risk reduction, and healthy lifestyles. These campaigns empower individuals to understand their risk factors and seek medical attention promptly, contributing to better prognosis and treatment outcomes.

Key Market Challenges

Late Diagnosis

Late diagnosis refers to the identification of endometrial cancer at an advanced stage, when the disease has progressed beyond its early, potentially curable phases. In the context of the global endometrial cancer market, late diagnosis poses significant challenges for both patients and the healthcare system. One key issue is that endometrial cancer often presents with vague or mild symptoms, such as abnormal vaginal bleeding or pelvic discomfort, which can be mistakenly attributed to other conditions or dismissed as part of the natural aging process. This lack of specific symptoms contributes to delays in seeking medical attention, allowing the cancer to grow and spread unnoticed. Late-stage diagnosis has several negative implications. It can limit treatment options. Cancers detected early are more likely to be treatable through less invasive interventions like surgery, hormonal therapy, or targeted treatments. However, advanced-stage cancers may necessitate more aggressive approaches like chemotherapy and radiation, which can be associated with more adverse effects and reduced chances of success. Late diagnosis often results in poorer prognosis and decreased survival rates. Advanced-stage endometrial cancer is more likely to have spread to nearby lymph nodes or distant organs, making it harder to eradicate completely. This translates to higher healthcare costs due to the need for more extensive treatments and longer hospital stays. Addressing late diagnosis requires heightened awareness among both healthcare providers and the general population about the risk factors and early warning signs of endometrial cancer.

Side Effects of Treatment

The side effects of treatment for endometrial cancer have significant implications for the global endometrial cancer market. These side effects are the unintended and often undesirable consequences that patients may experience because of undergoing various therapeutic interventions, such as surgery, chemotherapy, radiation therapy, and hormonal treatments. In the context of the global endometrial cancer market, the presence of treatment-related side effects can impact several aspects. Side effects can lead to decreased patient quality of life, potentially affecting adherence to treatment regimens. This can result in treatment interruptions or discontinuations, which in turn may compromise the effectiveness of the therapy and patient outcomes. The management of side effects often requires additional medical attention and interventions. This can lead to increased healthcare utilization, including hospital stays, doctor visits, and medications. The resulting healthcare costs can place a financial burden on both patients and healthcare systems, affecting the economics of the market. The presence of severe side effects can influence the development and adoption of new treatments. Drug developers and researchers must consider not only the therapeutic efficacy of a treatment but also its safety profile. If a treatment causes severe or intolerable side effects, its acceptance in the market might be limited, potentially affecting its commercial success.

Key Market Trends

Advancements in Personalized Medicine

Advancements in personalized medicine have emerged as a transformative trend in the global endometrial cancer market. Personalized medicine, also known as precision medicine, involves tailoring medical treatments and interventions to the individual characteristics of each patient. In the context of endometrial cancer, these advancements are changing the landscape of diagnosis, treatment selection, and patient outcomes. With the advent of advanced genomic sequencing technologies, researchers have gained a deeper understanding of the genetic and molecular variations that drive endometrial cancer's development and progression. This knowledge has paved the way for identifying specific genetic mutations, biomarkers, and molecular subtypes that are associated with the disease. These insights enable oncologists to make more informed decisions about treatment strategies. Genetic mutations and biomarkers that are unique to individual tumors can be targeted by specific drugs. These targeted therapies are designed to selectively attack cancer cells while minimizing damage to healthy cells, potentially improving treatment efficacy, and reducing side effects. Treatment Stratification: Personalized medicine allows for more precise stratification of patients based on their genetic profile. This leads to better identification of patients who are likely to respond to a particular treatment, optimizing treatment outcomes.

Personalized medicine has driven the design of clinical trials that focus on specific genetic or molecular characteristics. This approach enhances the likelihood of success by testing treatments on populations most likely to benefit. Personalized medicine enables monitoring of treatment response and disease progression in real-time, allowing for adjustments to treatment plans as needed. Predictive tools can help anticipate a patient's response to therapy. Personalized medicine helps avoid unnecessary treatments that might not be effective for certain patients. This not only reduces potential side effects but also optimizes healthcare resource utilization. Patients' individual characteristics can guide post-treatment follow-up plans, ensuring timely detection of recurrence and proactive management. In essence, advancements in personalized medicine are reshaping the global endometrial cancer market by shifting from a one-size-fits-all approach to a patient-centered, precise treatment paradigm. As research continues and technology improves, the potential for more effective, less toxic, and patient-friendly interventions grows, ultimately leading to improved outcomes and a more refined approach to managing endometrial cancer on a global scale.

Increased Emphasis on Early Detection

The increased emphasis on early detection is a pivotal trend in the global endometrial cancer market. Early detection refers to identifying the disease at its initial stages, before it has spread extensively, and when treatment options are more effective and less invasive. This trend has gained significant momentum due to its potential to improve patient outcomes, reduce treatment costs, and enhance the efficiency of the healthcare system. In the context of the global endometrial cancer market, several factors are driving this emphasis on early detection. Early-stage endometrial cancer is more likely to have favorable prognoses, as it's typically confined to the uterus. Detecting the disease early increases the chances of successful treatment, leading to improved long-term survival rates. Early-stage cancer often allows for less aggressive treatment options, such as minimally invasive surgery or hormone therapy, which can lead to quicker recovery times and better quality of life for patients. Treating advanced-stage cancers is more resource-intensive and costly. Early detection can reduce the need for extensive treatments, hospitalizations, and long-term care, resulting in significant cost savings for healthcare systems and patients.

Early detection can prevent the disease from progressing to more severe stages, thus reducing the physical and emotional burden on patients and their families. Healthcare organizations and advocacy groups are launching awareness campaigns to educate both healthcare providers and the public about the risk factors and symptoms of endometrial cancer. This leads to earlier recognition and diagnosis. Innovative diagnostic tools, such as imaging techniques, biomarker tests, and genetic profiling, enable earlier and more accurate detection of endometrial cancer. Early detection allows for the implementation of personalized surveillance plans for patients with a history of endometrial cancer, enabling the prompt identification of recurrences. By placing a stronger emphasis on early detection, the global endometrial cancer market aims to reduce the disease's impact on patients and society. Timely diagnosis facilitates less invasive treatments, higher survival rates, improved quality of life, and substantial cost savings. The ongoing development and adoption of effective early detection strategies have the potential to transform the way endometrial cancer is managed, leading to better patient outcomes and a more efficient healthcare ecosystem.

Segmental Insights

Therapy Insights

In 2023, the Endometrial Cancer Market witnessed the dominance of the chemotherapy segment due to several factors that contributed to its significant market share. Chemotherapy has long been a mainstay in the treatment of endometrial cancer, particularly in advanced stages or when the cancer has spread beyond the uterus. Its effectiveness in killing cancer cells throughout the body, including those that may have metastasized from the uterus to other organs, has established it as a cornerstone in the therapeutic arsenal against this disease.

One of the primary reasons for the continued expansion of the chemotherapy segment is its proven track record in improving survival rates and controlling the progression of endometrial cancer. Patients and healthcare providers often rely on chemotherapy as an adjuvant or neoadjuvant treatment to surgery, helping to shrink tumors before surgery or target any remaining cancer cells afterward. This dual role enhances its appeal and ensures its continued use in the treatment paradigm. The development of novel chemotherapy agents and regimens has brought renewed interest and optimism to this segment. Ongoing research and clinical trials have resulted in the discovery of more targeted and effective drugs with reduced side effects, improving patient outcomes and quality of life during treatment. The accessibility and familiarity of chemotherapy in clinical practice, along with its relatively established protocols, make it a reliable and preferred choice for many clinicians.

Cancer Type Insights

In 2023, in the global Endometrial Cancer Market, Endometrial Carcinoma emerges as the dominant cancer type. Endometrial Carcinoma refers to cancer that develops in the lining of the uterus, known as the endometrium. It accounts for the majority of endometrial cancer cases worldwide. Risk factors for Endometrial Carcinoma include obesity, hormonal imbalances, age, and genetic predisposition. Early detection and treatment are crucial for improving patient outcomes and reducing mortality rates associated with this cancer type. Treatment options for Endometrial Carcinoma typically include surgery, radiation therapy, chemotherapy, and hormone therapy, depending on the stage and severity of the cancer. Continuous research efforts aimed at understanding the underlying mechanisms of Endometrial Carcinoma and developing novel treatment approaches are essential for addressing this prevalent cancer and improving patient prognosis.

Regional Insights

The dominance of the North America segment in the Global Endometrial Cancer Market in 2023 and its predicted expansion in the coming years can be attributed to several key factors. North America boasts advanced healthcare infrastructure and a high level of awareness regarding endometrial cancer among both healthcare professionals and the general population. This heightened awareness leads to earlier detection and diagnosis, allowing for timely intervention and treatment initiation, which can positively impact patient outcomes.

The region has a strong emphasis on research and development (R&D) in the field of oncology, including endometrial cancer. This focus results in the continuous development of novel therapies, innovative treatment approaches, and clinical trials that contribute to the expansion of the market. Pharmaceutical companies and research institutions in North America are at the forefront of discovering and bringing new drugs to market, further solidifying the region's leading position.

The favorable reimbursement scenario in North America plays a significant role. The availability of insurance coverage and government support for cancer treatments, including endometrial cancer, ensures that patients have access to a wide range of treatment options without facing substantial financial burdens. This encourages both patients and healthcare providers to opt for advanced and often more expensive treatments, thereby driving market growth. The region's large population, particularly in the United States, also contributes to its dominance in the market. With a significant number of women at risk of endometrial cancer, there is a substantial market size for pharmaceutical companies to target. Collaborations between academic institutions, healthcare providers, and industry players in North America foster a conducive environment for the development and commercialization of endometrial cancer therapies.

Key Market Players

Elekta

Karyopharm Therapeutics Inc.

Eisai Co., Ltd

GSK plc

Siemens Healthineers AG

Johnson & Johnson

Boston Scientific Corporation

Pfizer Inc.

Bayer AG

Bristol-Myers Squibb Company

Report Scope:

In this report, the Global Endometrial Cancer Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Endometrial Cancer Market, By Cancer Type:

    Endometrial Carcinoma Uterine Sarcomas

Endometrial Cancer Market, By Therapy:

    Immunotherapy Radiation Therapy Chemotherapy Other Types of Therapies

Endometrial Cancer Market, By Diagnosis Method:

    Biopsy Pelvic Ultrasound Hysteroscopy CT scan Other Diagnosis Methods

Endometrial Cancer Market, By End Use:

    Hospitals Imaging Centers Others

Endometrial Cancer Market, By Region:

    North America

United States

Canada

Mexico

    Europe

France

United Kingdom

Italy

Germany

Spain

    Asia-Pacific

China

India

Japan

Australia

South Korea

    South America

Brazil

Argentina

Colombia

    Middle East & Africa

South Africa

Saudi Arabia

UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Endometrial Cancer Market.

Available Customizations:

Global Endometrial Cancer Market report with the given Market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional Market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, and Trends

4. Voice of Customer

5. Global Endometrial Cancer Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Cancer Type (Endometrial Carcinoma, Uterine Sarcomas)
    • 5.2.2. By Therapy (Immunotherapy, Radiation Therapy, Chemotherapy, Other Types of Therapies)
    • 5.2.3. By Diagnosis Method (Biopsy, Pelvic Ultrasound, Hysteroscopy, CT scan, Other Diagnosis Methods)
    • 5.2.4. By End Use (Hospitals, Imaging Centers, Others)
    • 5.2.5. By Company (2023)
    • 5.2.6. By Region
  • 5.3. Market Map

6. North America Endometrial Cancer Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Cancer Type
    • 6.2.2. By Therapy
    • 6.2.3. By Diagnosis Method
    • 6.2.4. By End Use
    • 6.2.5. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Endometrial Cancer Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Cancer Type
        • 6.3.1.2.2. By Therapy
        • 6.3.1.2.3. By Diagnosis Method
        • 6.3.1.2.4. By End Use
    • 6.3.2. Mexico Endometrial Cancer Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Cancer Type
        • 6.3.2.2.2. By Therapy
        • 6.3.2.2.3. By Diagnosis Method
        • 6.3.2.2.4. By End Use
    • 6.3.3. Canada Endometrial Cancer Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Cancer Type
        • 6.3.3.2.2. By Therapy
        • 6.3.3.2.3. By Diagnosis Method
        • 6.3.3.2.4. By End Use

7. Europe Endometrial Cancer Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Cancer Type
    • 7.2.2. By Therapy
    • 7.2.3. By Diagnosis Method
    • 7.2.4. By End Use
    • 7.2.5. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Endometrial Cancer Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Cancer Type
        • 7.3.1.2.2. By Therapy
        • 7.3.1.2.3. By Diagnosis Method
        • 7.3.1.2.4. By End Use
    • 7.3.2. Germany Endometrial Cancer Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Cancer Type
        • 7.3.2.2.2. By Therapy
        • 7.3.2.2.3. By Diagnosis Method
        • 7.3.2.2.4. By End Use
    • 7.3.3. United Kingdom Endometrial Cancer Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Cancer Type
        • 7.3.3.2.2. By Therapy
        • 7.3.3.2.3. By Diagnosis Method
        • 7.3.3.2.4. By End Use
    • 7.3.4. Italy Endometrial Cancer Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Cancer Type
        • 7.3.4.2.2. By Therapy
        • 7.3.4.2.3. By Diagnosis Method
        • 7.3.4.2.4. By End Use
    • 7.3.5. Spain Endometrial Cancer Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Cancer Type
        • 7.3.5.2.2. By Therapy
        • 7.3.5.2.3. By Diagnosis Method
        • 7.3.5.2.4. By End Use

8. Asia-Pacific Endometrial Cancer Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Cancer Type
    • 8.2.2. By Therapy
    • 8.2.3. By Diagnosis Method
    • 8.2.4. By End Use
    • 8.2.5. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Endometrial Cancer Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Cancer Type
        • 8.3.1.2.2. By Therapy
        • 8.3.1.2.3. By Diagnosis Method
        • 8.3.1.2.4. By End Use
    • 8.3.2. India Endometrial Cancer Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Cancer Type
        • 8.3.2.2.2. By Therapy
        • 8.3.2.2.3. By Diagnosis Method
        • 8.3.2.2.4. By End Use
    • 8.3.3. South Korea Endometrial Cancer Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Cancer Type
        • 8.3.3.2.2. By Therapy
        • 8.3.3.2.3. By Diagnosis Method
        • 8.3.3.2.4. By End Use
    • 8.3.4. Japan Endometrial Cancer Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Cancer Type
        • 8.3.4.2.2. By Therapy
        • 8.3.4.2.3. By Diagnosis Method
        • 8.3.4.2.4. By End Use
    • 8.3.5. Australia Endometrial Cancer Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Cancer Type
        • 8.3.5.2.2. By Therapy
        • 8.3.5.2.3. By Diagnosis Method
        • 8.3.5.2.4. By End Use

9. South America Endometrial Cancer Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Cancer Type
    • 9.2.2. By Therapy
    • 9.2.3. By Diagnosis Method
    • 9.2.4. By End Use
    • 9.2.5. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Endometrial Cancer Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Cancer Type
        • 9.3.1.2.2. By Therapy
        • 9.3.1.2.3. By Diagnosis Method
        • 9.3.1.2.4. By End Use
    • 9.3.2. Argentina Endometrial Cancer Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Cancer Type
        • 9.3.2.2.2. By Therapy
        • 9.3.2.2.3. By Diagnosis Method
        • 9.3.2.2.4. By End Use
    • 9.3.3. Colombia Endometrial Cancer Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Cancer Type
        • 9.3.3.2.2. By Therapy
        • 9.3.3.2.3. By Diagnosis Method
        • 9.3.3.2.4. By End Use

10. Middle East and Africa Endometrial Cancer Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Cancer Type
    • 10.2.2. By Therapy
    • 10.2.3. By Diagnosis Method
    • 10.2.4. By End Use
    • 10.2.5. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Endometrial Cancer Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Cancer Type
        • 10.3.1.2.2. By Therapy
        • 10.3.1.2.3. By Diagnosis Method
        • 10.3.1.2.4. By End Use
    • 10.3.2. Saudi Arabia Endometrial Cancer Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Cancer Type
        • 10.3.2.2.2. By Therapy
        • 10.3.2.2.3. By Diagnosis Method
        • 10.3.2.2.4. By End Use
    • 10.3.3. UAE Endometrial Cancer Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Cancer Type
        • 10.3.3.2.2. By Therapy
        • 10.3.3.2.3. By Diagnosis Method
        • 10.3.3.2.4. By End Use

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Porters Five Forces Analysis

  • 13.1. Competition in the Industry
  • 13.2. Potential of New Entrants
  • 13.3. Power of Suppliers
  • 13.4. Power of Customers
  • 13.5. Threat of Substitute Products

14. Competitive Landscape

  • 14.1. Elekta
    • 14.1.1. Business Overview
    • 14.1.2. Company Snapshot
    • 14.1.3. Products & Services
    • 14.1.4. Financials (As Reported)
    • 14.1.5. Recent Developments
    • 14.1.6. Key Personnel Details
    • 14.1.7. SWOT Analysis
  • 14.2. Karyopharm Therapeutics Inc.
  • 14.3. Eisai Co., Ltd
  • 14.4. GSK plc
  • 14.5. Siemens Healthineers AG
  • 14.6. Johnson & Johnson
  • 14.7. Boston Scientific Corporation
  • 14.8. Pfizer Inc.
  • 14.9. Bayer AG
  • 14.10. Bristol-Myers Squibb Company

15. Strategic Recommendations

16. About Us & Disclaimer